Trials / Completed
CompletedNCT02004041
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Proof of Concept, Antipruritic Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is randomized, double-blind, placebo-controlled study to test whether VLY-686 can reduce chronic pruritus in subjects with treatment-resistant pruritus associated with atopic dermatitis in comparison with placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VLY-686 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-12-10
- Primary completion
- 2015-02-19
- Completion
- 2015-02-19
- First posted
- 2013-12-06
- Last updated
- 2024-06-11
- Results posted
- 2024-06-11
Locations
5 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02004041. Inclusion in this directory is not an endorsement.